Lee Kyoung Eun Professor
College of Medicine
Professor Kyungeun Lee is a professor at department of pharmacology in Ewha womans university School of medicine. She graduated Ewha womans university school of medicine (M.D.), and got her Ph.D. degree at department of pharmacology in Yonsei university school of medicine. Her main research area is neuropsychophrmacology, and recently she is working with in vivo and/or ex vivo model of Alzheimer's dementia to evaulate the effects of autophay on the abeta-induced neuronal cell death. She's published over 40 original research articles and 5 books about pharmacology.
- Director for Clinical and Academic Affairs, College of Medicine
- Medical Science Building A #716
- 02-2650-5030
Research Record
- Evaluation of Group Genetic Counseling Sessions via a Metaverse-based Application Annals of Laboratory Medicine, 2024, v.44 no.1, 82-91
- Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial European Journal of Cancer, 2024, v.197, 113456
- A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03) Cancer research and treatment, 2023, v.55 no.2, 523-530
- Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16) European Journal of Cancer, 2023, v.195, 113386
- Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01) CANCERS, 2023, v.15 no.2, 471
- Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer Scientific Reports, 2023, v.13 no.1, 9928
- Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, v.14, 17588359221132600
- Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01) CANCER RESEARCH AND TREATMENT, 2022, v.54 no.1, 109-117
- Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma Cancer Research and Treatment, 2022, v.54 no.2, 597-612
- β‑catenin blockers enhance the effect of CDK4/6 inhibitors on stemness and proliferation suppression in endocrine‑resistant breast cancer cells Oncology reports, 2022, v.48 no.1
- Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12 CANCER RESEARCH AND TREATMENT, 2021, v.53 no.3, 671-677
- Choosing Wisely: The Korean Perspective and Launch of the 'Right Decision in Cancer Care' Initiative CANCER RESEARCH AND TREATMENT, 2020, v.52 no.3, 655-660
- Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18–12 Journal of Cancer Research and Clinical Oncology, 2020, v. 146 no.12, 0
- Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10) CANCERS, 2020, v.12 no.11, 3265
- Peroxiredoxin 3 has important roles on arsenic trioxide induced apoptosis in human acute promyelocytic leukemia cell line via hyperoxidation of mitochondrial specific reactive oxygen species Molecules and Cells, 2020, v.43 no.9, 813-820
- Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01) BMC CANCER, 2020, v.20 no.1, 813
- Human Epidermal Growth Factor Receptor 2-Subtype Invasive Ductal Carcinoma Recurring as Basal-Human Epidermal Growth Factor Receptor 2-Subtype Squamous Cell Carcinoma JOURNAL OF BREAST CANCER, 2019, v.22 no.3, 484-490
- Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial LANCET ONCOLOGY, 2019, v.20 no.12, 1750-1759
- Spindle cell sarcoma mimicking supraclavicular lymph node metastasis of breast cancer American Journal of Case Reports, 2019, v.20, 194-197
- Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial CANCER DISCOVERY, 2019, v.9 no.10, 1388-1405
- Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG) GASTRIC CANCER, 2018, v.21 no.5, 819-830
- Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01) Cancer, 2017, v. 123 no.11
- The enhanced tumor inhibitory effects of gefitinib and L-ascorbic acid combination therapy in non-small cell lung cancer cells ONCOLOGY LETTERS, 2017, v.14 no.1, 276-282
- A retrospective analysis for patients with HER2-positive gastric cancer who were treated with trastuzumab-based chemotherapy: In the perspectives of ethnicity and histology Cancer Research and Treatment, 2016, v.48 no.2, 553-560
- Current Status and Challenges of Cancer Clinical Trials in Korea CANCER RESEARCH AND TREATMENT, 2016, v.48 no.1, 20-27
- Germ Cell Tumor Targeting Chemotherapy in Gastric Adenocarcinoma with an Endodermal Sinus Tumor Component: A Case Report Chemotherapy, 2016, v.62 no.1, 54-57
- Inhibition of beta-Catenin to Overcome Endocrine Resistance in Tamoxifen-Resistant Breast Cancer Cell Line PLOS ONE, 2016, v.11 no.5
- MITOCHONDRIAL SPECIFIC ROS HYPEROXIDATION VIA PEROXIREDOXIN III HAS IMPORTANT ROLES ON ARSENIC TRIOXIDE INDUCED APOPTOSIS IN ACUTE PROMYELOCYTIC LEUKEMIA HAEMATOLOGICA, 2016, v.101, 672-672
- Manipulation of beta-catenin pathway to overcome endocrine resistance in breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 2015, v.33 no.15
- The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain Korean Journal of Internal Medicine, 2015, v.30 no.1, 88-95
- Meeting highlights: The first Korean breast cancer treatment consensus conference Journal of Breast Cancer, 2014, v.17 no.4, 308-313
- Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer TUMORI, 2014, v.100 no.1, 80-86
Courses
-
2024-1st
-
Introductory Clerkship
- Subject No 37637Class No 01
- 3Year ( 0.5Credit , 32Hour)
- Major Requisite
-
Internal Medicine Clerkship Ⅳ
- Subject No 37644Class No 01
- 3Year ( 4Credit , 220Hour)
- Major Requisite
-
Elective Courses
- Subject No 37668Class No 01
- 4Year ( 3Credit , 165Hour)
- Major Requisite
-
Subinternship
- Subject No 37681Class No 01
- 4Year ( 2Credit , 50Hour)
- Major Requisite
-
Genetic Disease and Genetic Counseling
- Subject No G17844Class No 01
- Year ( 3Credit , 3Hour) Thu 8~9
-
-
2023-2nd
-
Pathological Basis of Diseases
- Subject No 37603Class No 01
- 1Year ( 3Credit , 57Hour)
- Major Requisite
-
Hematology and Oncology
- Subject No 37624Class No 01
- 2Year ( 3Credit , 65Hour)
- Major Requisite
-
Symptomatology
- Subject No 37629Class No 01
- 2Year ( 1.5Credit , 23Hour)
- Major Requisite
-
Clinico-Pathologic ConferenceⅠ(CPCⅠ) 강의 계획서 상세보기
- Subject No 37639Class No 01
- 3Year ( 0.5Credit , 10Hour)
- Major Requisite
-
Internal Medicine Clerkship Ⅳ
- Subject No 37644Class No 01
- 3Year ( 4Credit , 220Hour)
- Major Requisite
-
End of Life Care (EOL)
- Subject No 37657Class No 01
- 3Year ( 1Credit , 22Hour)
- Major Requisite
-
Comprehensive Evaluation of Clinical Medicine Ⅱ
- Subject No 37679Class No 01
- 4Year ( 3Credit , 64Hour)
- Major Requisite
-
-
2023-1st
-
Internal Medicine Clerkship Ⅳ
- Subject No 37644Class No 01
- 3Year ( 4Credit , 220Hour)
- Major Requisite
-
Elective Courses
- Subject No 37668Class No 01
- 4Year ( 3Credit , 165Hour)
- Major Requisite
-
Subinternship
- Subject No 37681Class No 01
- 4Year ( 2Credit , 50Hour)
- Major Requisite
-
Genetic disease and Genetic counseling
- Subject No G17844Class No 01
- Year ( 3Credit , 3Hour) Thu 8~9
-
-
2022-2nd
-
Pathological Basis of Diseases
- Subject No 37603Class No 01
- 1Year ( 3Credit , 57Hour)
- Major Requisite
-
Hematology and Oncology
- Subject No 37624Class No 01
- 2Year ( 3Credit , 65Hour)
- Major Requisite
-
Symptomatology
- Subject No 37629Class No 01
- 2Year ( 1.5Credit , 28Hour)
- Major Requisite
-
Comprehensive evaluation of basic and clinical medicine
- Subject No 37633Class No 01
- 2Year ( 2Credit , 20Hour)
- Major Requisite
-
Internal Medicine Clerkship Ⅳ
- Subject No 37644Class No 01
- 3Year ( 4Credit , 220Hour)
- Major Requisite
-
End of Life Care (EOL)
- Subject No 37657Class No 01
- 3Year ( 1Credit , 22Hour)
- Major Requisite
-
-
2022-1st
-
Internal Medicine Clerkship Ⅳ
- Subject No 37644Class No 01
- 3Year ( 4Credit , 220Hour)
- Major Requisite
-
-
2021-2nd
-
Pathological Basis of Diseases
- Subject No 37603Class No 01
- 1Year ( 3Credit , 57Hour)
- Major Requisite
-
Hematology and Oncology
- Subject No 37624Class No 01
- 2Year ( 3Credit , 65Hour)
- Major Requisite
-
Symptomatology
- Subject No 37629Class No 01
- 2Year ( 1.5Credit , 28Hour)
- Major Requisite
-
Internal Medicine Clerkship Ⅳ
- Subject No 37644Class No 01
- 3Year ( 4Credit , 220Hour)
- Major Requisite
-
End of Life Care (EOL)
- Subject No 37657Class No 01
- 3Year ( 1Credit , 22Hour)
- Major Requisite
-
Genetic disease and Genetic counseling
- Subject No G17844Class No 01
- Year ( 3Credit , 3Hour) Mon 8~9 (-)
-
-
2021-1st
-
Internal Medicine Clerkship Ⅳ
- Subject No 37644Class No 01
- 3Year ( 4Credit , 220Hour)
- Major Requisite
-
Academic Background
Seoul Nat'l Univ. 의학박사(의학과)
Ewha Womans University 의학석사(의학과)
Ewha Womans University 의학사(의학과)